| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5743 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2005-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2008-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2008545615-A |
| titleOfInvention |
Cytotoxic mediation of cells demonstrating surface expression of CD63 |
| abstract |
The present invention relates to the diagnosis and treatment of cancerous diseases, in particular to mediating tumor cell cytotoxicity, and in particular to cancerous disease modification, optionally in combination with one or more chemotherapeutic agents as a means of initiating a cytotoxic response. It relates to the use of antibodies (CDMAB). The present invention further relates to binding assays utilizing the CDMAB of the present invention. [Selection] Figure 25 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013099925-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2013099925-A1 |
| priorityDate |
2005-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |